This information was published on 2026-02-23T13:46:50 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2622871 (IR 1899168) |
| (220) |
22 Dec 2025
|
| (300) |
US, 26 Jun 2025, 99255444
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment of endocrine and respiratory diseases and disorders, including autosomal dominant hypocalcemia type 1, hypoparathyroidism, and eosinophilic asthma. |
| (540) | KALSTEDI |
| (550) | Word |
| (730) |
Bridgebio Pharma, Inc.
|
Find out more about publications on the About page.